Pre-Exposure Prophylaxis study (treated before exposed to the virus)
et al., J. Medical Virology, July 9, 2020, doi:10.1002/jmv.26286 (preprint 6/29) (Peer Reviewed)
Chronic treatment with hydroxych loroquine and SARS-CoV-2 infection
Chronic treatment with HC Q provides protection against COVID, odds ratio 0.51 (0.37-0.70). Note that patients with SLE, RA, and other autoimmune conditions have a significantly increased susceptibility to and incidence of infections, so the actual benefit may be significantly higher [1, 2, 3, 4, 5, 6, 7].
Please send us corrections, updates, or comments.